SG11201907638QA - Proteins binding cd33, nkg2d and cd16 - Google Patents
Proteins binding cd33, nkg2d and cd16Info
- Publication number
- SG11201907638QA SG11201907638QA SG11201907638QA SG11201907638QA SG11201907638QA SG 11201907638Q A SG11201907638Q A SG 11201907638QA SG 11201907638Q A SG11201907638Q A SG 11201907638QA SG 11201907638Q A SG11201907638Q A SG 11201907638QA SG 11201907638Q A SG11201907638Q A SG 11201907638QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- lebanon
- lucent
- pct
- drive
- Prior art date
Links
- 230000027455 binding Effects 0.000 title abstract 2
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 abstract 2
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 abstract 2
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 abstract 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 abstract 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 abstract 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 abstract 1
- 108010001657 NK Cell Lectin-Like Receptor Subfamily K Proteins 0.000 abstract 1
- 102000000812 NK Cell Lectin-Like Receptor Subfamily K Human genes 0.000 abstract 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 102000023732 binding proteins Human genes 0.000 abstract 1
- 108091008324 binding proteins Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000009870 specific binding Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Display Devices Of Pinball Game Machines (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762461145P | 2017-02-20 | 2017-02-20 | |
| PCT/US2018/018768 WO2018152516A1 (en) | 2017-02-20 | 2018-02-20 | Proteins binding cd33, nkg2d and cd16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907638QA true SG11201907638QA (en) | 2019-09-27 |
Family
ID=63169992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907638QA SG11201907638QA (en) | 2017-02-20 | 2018-02-20 | Proteins binding cd33, nkg2d and cd16 |
Country Status (12)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| EP4273258A3 (en) | 2017-02-20 | 2024-01-17 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
| FI3749346T3 (fi) | 2018-02-08 | 2024-09-04 | Dragonfly Therapeutics Inc | Nkg2d-reseptoriin kohdistuvat vasta-aineen vaihtelevan domeenin yhdistelmät |
| EA202091887A1 (ru) | 2018-02-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры |
| TW201942134A (zh) | 2018-02-20 | 2019-11-01 | 美商蜻蜓醫療公司 | 結合cd33、nkg2d及cd16之多特異性結合蛋白及使用方法 |
| EA202091977A1 (ru) * | 2018-05-28 | 2021-02-09 | Драгонфлай Терапьютикс, Инк. | Мультиспецифические связывающие белки, которые связывают cd33, nkg2d и cd16, и способы применения |
| TW202019479A (zh) | 2018-08-08 | 2020-06-01 | 美商蜻蜓醫療公司 | 結合bcma、nkg2d及cd16之多特異性結合蛋白及使用方法 |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| KR102835308B1 (ko) | 2018-08-08 | 2025-07-21 | 드래곤플라이 쎄라퓨틱스, 인크. | Nkg2d, cd16 및 종양 관련 항원에 결합하는 단백질 |
| CN113227141A (zh) * | 2018-11-07 | 2021-08-06 | 克里斯珀医疗股份公司 | 抗cd33免疫细胞癌症疗法 |
| CN113121697B (zh) * | 2019-12-31 | 2023-06-09 | 周易 | Ch3结构域改造诱导形成的异源二聚体及其制备方法和应用 |
| WO2021226193A1 (en) | 2020-05-06 | 2021-11-11 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and clec12a |
| US20230391866A1 (en) * | 2020-07-03 | 2023-12-07 | The Trustees Of Columbia University In The City Of New York | Polyfunctional orthogonal protein chimeras |
| CN117222663A (zh) | 2021-03-03 | 2023-12-12 | 蜻蜓疗法股份有限公司 | 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法 |
| CN115197330B (zh) * | 2021-04-14 | 2023-04-28 | 广州百暨基因科技有限公司 | 同时靶向cll1和cd33的嵌合抗原受体及其应用 |
| CN116948029A (zh) * | 2022-04-20 | 2023-10-27 | 南京融捷康生物科技有限公司 | 一种包含IgG类Fc区变体的抗体及其用途 |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024249954A1 (en) | 2023-05-31 | 2024-12-05 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025179294A2 (en) | 2024-02-22 | 2025-08-28 | Capstan Therapeutics, Inc. | Immune engineering amplification |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ20023203A3 (cs) * | 2000-03-24 | 2003-08-13 | Micromet Ag | Multifunkční polypeptidy obsahující vazebné místo k epitopu receptorového komplexu NKG2D |
| CL2007002668A1 (es) * | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| BRPI0821658B8 (pt) * | 2007-12-14 | 2021-05-25 | Novo Nordisk As | anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos |
| UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
| DE102009045006A1 (de) * | 2009-09-25 | 2011-04-14 | Technische Universität Dresden | Anti-CD33 Antikörper und ihre Anwendung zum Immunotargeting bei der Behandlung von CD33-assoziierten Erkrankungen |
| EP2332994A1 (en) * | 2009-12-09 | 2011-06-15 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Trispecific therapeutics against acute myeloid leukaemia |
| IL284301B1 (en) * | 2013-03-15 | 2025-06-01 | Xencor Inc | Heterodimeric proteins |
| WO2014198748A1 (en) * | 2013-06-11 | 2014-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-her2 single domain antibodies, polypeptides comprising thereof and their use for treating cancer |
| DK3126384T3 (da) * | 2014-04-01 | 2021-01-18 | Adimab Llc | Multispecifikke antistofanaloger omfattende en fælles letkæde, og fremgangsmåder til deres fremstilling og anvendelse |
| BR112016027893A2 (pt) * | 2014-05-29 | 2017-10-24 | Macrogenics Inc | molécula de ligação triespecífica, e, composição farmacêutica |
| EP2985294A1 (en) * | 2014-08-14 | 2016-02-17 | Deutsches Krebsforschungszentrum | Recombinant antibody molecule and its use for target cell restricted T cell activation |
| JP6919118B2 (ja) * | 2014-08-14 | 2021-08-18 | ノバルティス アーゲー | ＧＦＲα−４キメラ抗原受容体を用いる癌の治療 |
| ES2688035T3 (es) * | 2014-08-29 | 2018-10-30 | Gemoab Monoclonals Gmbh | Receptor de antígeno universal que expresa células inmunes para direccionamiento de antígenos múltiples diversos, procedimiento para fabricación del mismo y utilización del mismo para tratamiento de cáncer, infecciones y enfermedades autoinmunes |
| ES2717308T3 (es) * | 2014-12-06 | 2019-06-20 | Gemoab Monoclonals Gmbh | Células madre pluri- o multi-potentes genéticamente modificadas y sus usos |
| CN107530424A (zh) * | 2015-02-20 | 2018-01-02 | 俄亥俄州国家创新基金会 | 针对nkg2d和肿瘤相关抗原的二价抗体 |
| KR20240013282A (ko) * | 2015-06-10 | 2024-01-30 | 이뮤너티바이오, 인크. | 암을 치료하기 위한 변형된 nk-92 세포 |
| JP6840682B2 (ja) * | 2015-06-23 | 2021-03-10 | イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． | 多重特異的抗原結合タンパク質 |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| CN110944651A (zh) * | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
-
2018
- 2018-02-20 AU AU2018220734A patent/AU2018220734B2/en not_active Expired - Fee Related
- 2018-02-20 WO PCT/US2018/018768 patent/WO2018152516A1/en not_active Application Discontinuation
- 2018-02-20 EP EP18753685.9A patent/EP3583131A4/en active Pending
- 2018-02-20 JP JP2019545316A patent/JP2020510646A/ja active Pending
- 2018-02-20 US US16/486,921 patent/US20210130471A1/en not_active Abandoned
- 2018-02-20 SG SG11201907638QA patent/SG11201907638QA/en unknown
- 2018-02-20 BR BR112019017277A patent/BR112019017277A2/pt unknown
- 2018-02-20 KR KR1020197026921A patent/KR20190120775A/ko not_active Ceased
- 2018-02-20 MA MA047508A patent/MA47508A/fr unknown
- 2018-02-20 CN CN201880026148.9A patent/CN110573530A/zh active Pending
- 2018-02-20 CA CA3054078A patent/CA3054078A1/en active Pending
-
2019
- 2019-08-19 IL IL26879019A patent/IL268790A/en unknown
-
2023
- 2023-01-05 JP JP2023000416A patent/JP2023052214A/ja active Pending
-
2025
- 2025-01-07 JP JP2025002125A patent/JP2025061059A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023052214A (ja) | 2023-04-11 |
| KR20190120775A (ko) | 2019-10-24 |
| WO2018152516A1 (en) | 2018-08-23 |
| EP3583131A4 (en) | 2021-03-17 |
| BR112019017277A2 (pt) | 2020-04-14 |
| MA47508A (fr) | 2021-03-17 |
| RU2019129174A3 (enrdf_load_stackoverflow) | 2021-07-02 |
| IL268790A (en) | 2019-10-31 |
| JP2020510646A (ja) | 2020-04-09 |
| US20210130471A1 (en) | 2021-05-06 |
| CN110573530A (zh) | 2019-12-13 |
| AU2018220734B2 (en) | 2025-03-06 |
| EP3583131A1 (en) | 2019-12-25 |
| RU2019129174A (ru) | 2021-03-22 |
| JP2025061059A (ja) | 2025-04-10 |
| CA3054078A1 (en) | 2018-08-23 |
| AU2018220734A1 (en) | 2019-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907638QA (en) | Proteins binding cd33, nkg2d and cd16 | |
| SG11201907253VA (en) | Proteins binding bcma, nkg2d and cd16 | |
| SG11201907646YA (en) | Proteins binding her2, nkg2d and cd16 | |
| SG11201907271PA (en) | Proteins binding psma, nkg2d and cd16 | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201907648XA (en) | Proteins binding gd2, nkg2d and cd16 | |
| SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
| SG11201907645PA (en) | Proteins binding cd123, nkg2d and cd16 | |
| SG11201907948TA (en) | Formulations comprising pd-1 binding proteins and methods of making thereof | |
| SG11201903867YA (en) | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) | |
| SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
| SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
| SG11201907848YA (en) | Antibodies binding to vista at acidic ph | |
| SG11201810933QA (en) | Anti-c5 antibodies and uses thereof | |
| CA3015496A1 (en) | Voice control of a media playback system | |
| SG11201810687SA (en) | Serum albumin-binding fibronectin type iii domains | |
| SG11201804375WA (en) | Compositions and methods for internalizing enzymes | |
| SG11201906947SA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201903771XA (en) | Binding molecules specific for asct2 and uses thereof | |
| SG11201808014SA (en) | Compositions, devices, and methods for cell separation | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201808821WA (en) | Agonistic antibodies that bind human cd40 and uses thereof | |
| SG11201900746RA (en) | Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions | |
| SG11201900501RA (en) | Cannabis composition | |
| SG11201908743SA (en) | Methods and compositions for modulation of immune cells |